> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Danaher Adds Former CFO Comas And Biotech Executive Hershberg, Lifting Board To 13 Seats
- URL: https://www.bullished.co/danaher-adds-former-cfo-comas-and-biotech-executive-hershberg-lifting-board-to-13-seats-4a509fa6/
- Published: 2026-10-13T13:06:09.000Z
- Updated: 2026-10-28T22:16:57.000Z
- Description: Both directors took seats Friday, the founders gave up 500,000 stock units each, and director Alan Spoon plans to retire in 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, DHR, Industry: Healthcare

[Danaher](https://www.bullished.co/tag/dhr/)'s board [grew from 11 seats to 13](https://www.prnewswire.com/news-releases/danaher-announces-appointments-of-daniel-comas-and-robert-hershberg-to-board-of-directors-302906121.html?ref=bullished.co) on October 9, when it appointed former chief financial officer Daniel L. Comas and biotech executive Robert M. Hershberg, according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) the company filed Tuesday. The same filing says co-founders Steven and Mitchell Rales each gave up 500,000 restricted stock units, and director Alan Spoon will retire at the 2027 annual meeting.

## Two new directors, one new committee seat

Both appointments took effect immediately and run until the next annual meeting of shareholders. Hershberg also joins the board's Science and Technology Committee.

Comas, 62, joined Danaher in 1991\. He was an executive vice president from April 2005 through December 2020, and chief financial officer from April 2005 through December 2018\. He also sits on the boards of Fortive, since March 2021, and Veralto, since September 2023.

Hershberg, 63, was president, CEO and chairman of HilleVax from March 2020 through September 2025\. Before that he held senior roles at Celgene, including executive vice president and chief scientific officer. He is a senior advisor to Frazier Life Sciences and a director of Adaptive Biotechnologies and Recursion Pharmaceuticals.

Each will be paid under the non-employee director program, with cash prorated from the appointment date and an equity award prorated for the days between October 9, 2026, and May 15, 2027.

## Comas's consulting pay and the founders' waiver

Comas kept a paid link to Danaher after leaving management. He worked as a non-executive senior advisor from January 2021 through March 2024, then, after retiring in March 2024, served as a consultant under an April 2024 agreement for strategic advice.

The filing says he earned [$525,000](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000193/dhr-20261009.htm?ref=bullished.co) under that agreement in 2025 and $393,750 in 2026\. He and the company mutually ended it effective September 30, 2026, in connection with his joining the board. The filing reports no other transactions involving either new director that it must disclose.

Steven Rales, chairman and co-founder, and Mitchell Rales, chairman of the executive committee and co-founder, were each granted restricted stock units covering [500,000 shares](https://www.prnewswire.com/news-releases/danaher-announces-appointments-of-daniel-comas-and-robert-hershberg-to-board-of-directors-302906121.html?ref=bullished.co) on August 4, alongside stock options. On October 9, each waived the units for no consideration. The filing does not mention the options in connection with the waiver.

## Spoon's exit and what comes next

Spoon told the company on October 9 that he will retire from the board effective at the 2027 annual meeting and will not stand for re-election. The filing says the decision is not due to a disagreement over operations, policies, practices or any committee matter.

Danaher's Nominating & Governance Committee said it continues to evaluate board composition as part of regular governance and refreshment.

Spoon stays on the board until the 2027 annual meeting, so the board remains at 13 seats until then.

Learn

- [Item 5.02: directors and officers leave or join, or executive pay is set →](https://www.bullished.co/learn/8-k-items-explained/#item-502-directors-and-officers-leave-or-join-or-executive-pay-is-set)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — DANAHER CORP /DE/ (DHR)](https://www.sec.gov/Archives/edgar/data/0000313616/000031361626000193/dhr-20261009.htm?ref=bullished.co) — SEC EDGAR
- [Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors](https://www.prnewswire.com/news-releases/danaher-announces-appointments-of-daniel-comas-and-robert-hershberg-to-board-of-directors-302906121.html?ref=bullished.co) — prnewswire.com

### More on Danaher

- [Danaher's New CEO Says Growth Fell Short Of Portfolio's 'Full Potential' And Names Share Gain Her 'Report Card'](https://www.bullished.co/danahers-new-ceo-says-growth-fell-short-of-portfolios-full-potential-and-names-share-gain-ab8ddb5f/)
- [Danaher's Tax Line Swung To A $75 Million Benefit As Diagnostics Margin Fell To 21.3%](https://www.bullished.co/danahers-tax-line-swung-to-a-75-million-benefit-as-diagnostics-margin-fell-to-21-3-227fe7ca/)
- [Danaher Lifts 2026 Adjusted EPS Outlook To $8.57-$8.62 As Core Growth Ex-Respiratory Hits 5.5%](https://www.bullished.co/danaher-lifts-2026-adjusted-eps-outlook-to-8-57-8-62-as-core-growth-ex-respiratory-hits-5-baa72797/)

[All Danaher (DHR) coverage →](https://www.bullished.co/tag/dhr/)